European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
1. EPO confirmed the validity of CureVac's patent EP 3 708 668 B1. 2. BioNTech's opposition to the patent was largely dismissed by the EPO. 3. A court hearing on patent infringement is scheduled for July 2025. 4. CureVac settled a lawsuit regarding COVID-19 vaccine credit last April. 5. CVAC shares rose 17.5% following the patent confirmation news.